S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Fate Therapeutics Stock Price, News & Analysis (NASDAQ:FATE)

$2.37
-0.17 (-6.69%)
(As of 12/5/2023 ET)
Compare
Today's Range
$2.35
$2.55
50-Day Range
$1.65
$2.65
52-Week Range
$1.63
$20.73
Volume
1.18 million shs
Average Volume
2.64 million shs
Market Capitalization
$233.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.44

Fate Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.15 Rating Score
Upside/​Downside
340.4% Upside
$10.44 Price Target
Short Interest
Bearish
12.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.79) to ($2.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

293rd out of 948 stocks

Biological Products, Except Diagnostic Industry

45th out of 147 stocks


FATE stock logo

About Fate Therapeutics Stock (NASDAQ:FATE)

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Stock Price History

FATE Stock News Headlines

Fate Therapeutics: Getting There, But Perpetually
Fate Therapeutics Inc FATE
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
TD Cowen Keeps Their Hold Rating on Fate Therapeutics (FATE)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Fate Therapeutics: Not Now, Maybe Never?
The Latest Analyst Ratings for Fate Therapeutics
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
551
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.44
High Stock Price Target
$65.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+340.4%
Consensus Rating
Hold
Rating Score (0-4)
2.15
Research Coverage
20 Analysts

Profitability

Net Income
$-281,720,000.00
Net Margins
-163.04%
Pretax Margin
-163.04%

Debt

Sales & Book Value

Annual Sales
$96.30 million
Book Value
$4.98 per share

Miscellaneous

Free Float
93,632,000
Market Cap
$233.68 million
Optionable
Optionable
Beta
1.57
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














FATE Stock Analysis - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price target for 2024?

20 brokerages have issued 12-month price targets for Fate Therapeutics' shares. Their FATE share price targets range from $3.00 to $65.00. On average, they anticipate the company's share price to reach $10.44 in the next twelve months. This suggests a possible upside of 340.4% from the stock's current price.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2023?

Fate Therapeutics' stock was trading at $10.09 at the start of the year. Since then, FATE stock has decreased by 76.5% and is now trading at $2.37.
View the best growth stocks for 2023 here
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.13. The biopharmaceutical company earned $1.94 million during the quarter, compared to the consensus estimate of $0.99 million. Fate Therapeutics had a negative net margin of 163.04% and a negative trailing twelve-month return on equity of 38.44%.

What ETF holds Fate Therapeutics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (2.49%), Jacobs Levy Equity Management Inc. (2.42%), Acadian Asset Management LLC (2.18%), Monaco Asset Management SAM (1.87%), Charles Schwab Investment Management Inc. (0.90%) and Healthcare of Ontario Pension Plan Trust Fund (0.45%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:FATE) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -